Doctor Jeanmarie Guenot’s Current Exploits: Consequences of Past Impeccable Attainments

JeanMarie Guenot has been replicating the qualities everybody knows about her since joining Amphivena Therapeutics as CEO and President. It came as no surprise because she has a solid foundation. Guenot together with her team in Amphivena is helping to curb the spread of cancer, and hopefully, eradicate it altogether in the nearest future.

Statistics about cancer cases is not encouraging with 19 million people expected to be diagnosed with it by the year 2024. Amphivena Therapeutics under the leadership of JeanMarie Guenot is leaving no stone unturned by joining forces with multiple alliances so as to bring together massive resources and know-how in the fight against this horrible disease.

On the 10th of August, 2016, it was in the news that the U.S. Food and Drug Administration (FDA) approved an investigational new drug application for AMV564, the Amphivena Therapeutics’ proprietary antibody. AMV564 is a bispecific antibody that makes use of T-cells in getting rid of cancer cells with CD33. CD33 is a particular receptor commonly found in most cases of AMLs, which is also expressed on other hematological malignancies.

Also, on the 7th of April, 2015, according to guenotllc.com, Amphivena Therapeutics, Inc. made public some milestones achievement under the terms of agreement between Janssen Biotech, Inc and itself. Janssen and Amphivena, in furtherance of development in hematologic malignancies, selected a clinical candidate against an unnamed tumor antigen. The milestones came with financial benefits for Amphivena.

Guenot’s wealth of experience in the pharmaceutical and biotechnology industry started with Atlas Venture while she was managing its venture capital investments. She also spent time working as a scientist with the Preclinical Research and Development arm of Hoffman LaRoache. Hoffman LaRoache is a company that focuses on dry AMD together with sustained release ocular drug delivery technologies for macular degeneration, ocular inflammation and glaucoma. Today, she is in a firm that develops cancer immunotherapies.

JeanMarie Guenot holds a PhD and MBA from the University of California, San Francisco and the Wharton School at the University of Pennsylvania.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

USHEALTH Group’s President Troy McQuagge Is Honored As CEO Of The Year

Troy McQuagge, the CEO of USHEALTH Group Inc has been announced by the One Planet Awards as the CEO of the Year. He was the Gold Winner during the high-status One Planet Awards, which is a leading awards program in the world. One Planet Awards honors business and professional brilliance in each industry internationally.

Presently, the honors are given to different categories, including teams, executives, PR, marketing, new products and services, and corporate communications. Organizations across the globe are entitled to submit their nominations. Such entities comprise of all sizes, for- profit, non-profit, public, as well as private organizations.

Troy McQuagge joined USHEALTH in 2010. McQuagge’s immediate task was facilitating the company’s turnaround by revamping USHEALTH Advisors, its distribution agency. His success with this initial task led to his selection as the USHEALTH’s president and CEO in 2014. Under his guidance, the company has registered success in terms of profitability and growth in the individual health insurance industry.

Receiving the award, McQuagge pointed out that the recognition from One Planet Awards was a great honor. He was pleased to receive the industry recognition. McQuagge said that the award belonged to the entire team at USHEALTH. This was a testament to the firm’s ongoing dedication to providing the public with innovative services and products. The corporation endeavors to find a solution to the problem of healthcare affordability by offering customers with an innovative coverage.

About Troy McQuagge

Troy McQuagge doubles up as the president and the chief executive officer of USHEALTH Group, Inc.  McQuagge has been in the management team of the company since 2014. As the head of the firm, McQuagge is in charge of USHEALTH Group Inc’s strategic growth. He is responsible for the firm’s fully owned subsidiary, which deals with insurance operations and distribution. Under McQuagge’s guidance, USHEALTH Group has recorded unprecedented outcomes. In the last three years, he has helped in enhancing the corporation’s performance. From 2010 to 2014, McQuagge served as the president and chief executive officer of USHEALTH Advisors where he focused on individuals below 65 years.

Previously, McQuagge served as the president of agency marketing of HealthMarket. He has worked in the sales department for more than 30 years. McQuagge is an alumnus of the esteemed University of Central Florida. He joined the health insurance sales industry immediately after graduating.  He worked for the company for over ten years before joining HealthMarket in 1995. In his career, McQuagge has won many awards. These awards include the CEO World Awards’ Gold Award-CEO of the Year in 2016 and Most Innovative CEO of the Year.